Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127013002 | 12701300 | 2 | F | 201607 | 20160830 | 20160831 | 20160906 | EXP | BE-ROCHE-1820854 | ROCHE | 56.00 | YR | F | Y | 0.00000 | 20160906 | OT | BE | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127013002 | 12701300 | 1 | PS | LUCENTIS | RANIBIZUMAB | 1 | Unknown | UNK | Y | U | 125156 | SOLUTION FOR INJECTION | /month | ||||||
| 127013002 | 12701300 | 2 | SS | LUCENTIS | RANIBIZUMAB | 1 | Unknown | UNK | Y | U | 125156 | SOLUTION FOR INJECTION | /month | ||||||
| 127013002 | 12701300 | 3 | SS | FLAGYL | METRONIDAZOLEMETRONIDAZOLE HYDROCHLORIDE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127013002 | 12701300 | 1 | Retinopathy |
| 127013002 | 12701300 | 3 | Vaginal infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127013002 | 12701300 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127013002 | 12701300 | Anxiety | |
| 127013002 | 12701300 | Dysaesthesia | |
| 127013002 | 12701300 | Dyspnoea | |
| 127013002 | 12701300 | Feeling abnormal | |
| 127013002 | 12701300 | Gait disturbance | |
| 127013002 | 12701300 | Grip strength decreased | |
| 127013002 | 12701300 | Hemiplegia | |
| 127013002 | 12701300 | Hypothyroidism | |
| 127013002 | 12701300 | Inappropriate schedule of drug administration | |
| 127013002 | 12701300 | Muscular weakness | |
| 127013002 | 12701300 | Musculoskeletal stiffness | |
| 127013002 | 12701300 | Myalgia | |
| 127013002 | 12701300 | Nasal congestion | |
| 127013002 | 12701300 | Pain | |
| 127013002 | 12701300 | Retinopathy | |
| 127013002 | 12701300 | Tongue paralysis | |
| 127013002 | 12701300 | Urticaria | |
| 127013002 | 12701300 | Vaginal infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127013002 | 12701300 | 1 | 201603 | 201603 | 0 | |
| 127013002 | 12701300 | 2 | 20160718 | 20160718 | 0 |